Market News & Trends
WACKER & CordenPharma Develop Solutions for Formulating Lipid Nanoparticles, Expanding Their Portfolio for Advanced Medicines
WACKER and CordenPharma have signed a development partnership in the field of Lipid Nanoparticle formulation. The two companies announced they plan to jointly develop know-how…
Immunic, Inc. Publishes Positive Results From the Single & Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Immunic, Inc. recently announced positive unblinded safety, tolerability and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD)…
Immatics & Bristol Myers Squibb Enter Global Exclusive License for TCR Bispecific Program IMA401
Immatics N.V. and Bristol Myers Squibb recently announced they have entered into a license, development, and commercialization agreement for Immatics’ TCR Bispecific candidate, IMA401…..
TheraPanacea & Biogen Announce New Collaboration With the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Biogen Inc. and TheraPanacea recently announced they have entered into a collaboration focused on multiple therapeutic areas in neuroscience, to further build on the companies’ existing relationship…..
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
Adagio Therapeutics, Inc. recently provided an update following external in vitro analyses to evaluate neutralizing activity of ADG20 against the Omicron SARS-CoV-2 variant. The in…
KemPharm Announces Top-Line Results From Clinical Trial Evaluating the Safety & Pharmacokinetics of Higher-Dose SDX
KemPharm, Inc. recently announced top-line results from its clinical trial exploring the safety and pharmacokinetics of serdexmethylphenidate (SDX) delivered at doses higher than those studied…
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated With Schizophrenia
atai Life Sciences recently announced positive topline data from its Phase 2a study of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS). The 32-patient, single-arm,…
HiberCell to Collaborate With Merck on Phase 2 Clinical Trial of Odetiglucan in Combination With KEYTRUDA in Patients With Metastatic Breast Cancer
HiberCell recently announced a clinical trial collaboration with Merck. This metastatic breast cancer clinical trial evaluates KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with….
Vaccitech Acquires Avidea Technologies to Expand Product Pipeline & Strengthen Scientific Leadership in Immunotherapies & Vaccines
Vaccitech plc recently announced that it has acquired US-based Avidea Technologies, Inc. The consideration to Avidea’s existing shareholders is $40 million….
Pfizer to Acquire Arena Pharmaceuticals for $6.7 Billion
Pfizer Inc. and Arena Pharmaceuticals, Inc. recently announced the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical-stage company developing….
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
Precision BioSciences, Inc. recently announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD) presented at….
Akoya Biosciences Announces Groundbreaking Collaboration With PathAI to Combine Spatial Biology With AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers
Akoya Biosciences, Inc. and PathAI recently announced a collaboration to advance the discovery and validation of novel predictive biomarkers for immunotherapies. The partners will leverage…
NextCure & Collaborators Provide Data on Targets in Development
NextCure, Inc. recently announced new data in oral and poster presentations at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, and on…
Arrivo BioVentures Emerges From Stealth Mode With a Robust Pipeline & Promising Data
After launching the company over 5 years ago with a team of seasoned serial entrepreneurs, $49 million in committed capital, and the promise to assemble…
Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
Halberd Corporation has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune…
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination With Pembrolizumab in Metastatic Breast Cancer
Intensity Therapeutics, Inc. recently reported safety, pharmacokinetic, biomarker, and efficacy data using INT230-6, with and without pembrolizumab, in heavily pretreated refractory breast cancer patients as part of the….
Fareva & ApiJect Sign Licensing Agreement to Create a France-Based 500-Million Unit Annual Capacity for Single-Dose Prefilled Vaccine Injections
Fareva and ApiJect Systems, Corp. recently announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and….
London Heathrow Airport’s CEO, John Holland-Kaye, Pays a Visit to Micropore Technologies
Following its award as a Global Britain Business Champion by London’s Heathrow Airport, Micropore Technologies was delighted to host a personal visit by Heathrow’s CEO…
UniQure Announces Pivotal Phase 3 HOPE-B Study Meets Primary Endpoint for Hemophilia B Gene Therapy
CSL Behring and uniQure N.V. recently announced that etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe to moderately…
CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating Selective Aldosterone Synthase Inhibitor in Patients With Uncontrolled Hypertension & High Plasma Aldosterone
CinCor Pharma, Inc. recently announced the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective, oral small molecule…
